Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 73Carcinoma, Hepatocellular 67Stomach Neoplasms 52Pancreatic Neoplasms 40Rectal Neoplasms 30Colonic Neoplasms 30Neoplasms 21Liver Neoplasms 20Esophageal Neoplasms 19Neoplasm Metastasis 16Cholangiocarcinoma 16Esophageal Squamous Cell Carcinoma 14Gallbladder Neoplasms 12Biliary Tract Neoplasms 12Lung Neoplasms 10Gastrointestinal Neoplasms 7Adenocarcinoma Of Esophagus 7Ovarian Neoplasms 6Prostatic Neoplasms 5Neoplasms by Site 5Bile Duct Neoplasms 5Adenocarcinoma 5Polyps 4Neoplasms by Histologic Type 4Melanoma 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Adenoma 4Recurrence 3

Interventions

Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Familial Mediterranean Fever × Gastrointestinal × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡